GleamWall
中文EN

AIM AIM ImmunoTech Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 946644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.8%
TTM net income YoY10.3%
TTM EPS YoY93.4%
Revenue 3-yr CAGR-22.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12,800.0%
Net margin-15,526.4%
FCF margin—
EBITDA margin-11,853.8%

Returns

ROE-2,828.6%
ROA-185.4%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets27.4%
Debt / equity0.41x
Current ratio2.75x
Interest coverage-9.33x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$88,000$170,000
R&D expense$3.92M$6.20M
SG&A expense$7.70M$13.71M
Operating income-$11.66M-$19.77M
Interest expense$812,000$585,000
Pretax income-$13.96M—
Net income-$13.96M-$17.32M
EBITDA-$11.63M-$19.73M
EPS (basic)-8.62-30.92
EPS (diluted)-8.62-30.92
Weighted avg. shares (diluted)1.62M560,169
Balance sheet
Cash & equivalents$2.98M$1.70M
Short-term investments$62,000$2.28M
Receivables$7,000—
Current assets$3.29M$4.18M
PP&E, net$71,000$108,000
Intangibles$1.66M$2.59M
Total assets$5.78M$8.61M
Current liabilities$6.22M$9.54M
Short-term debt$3.55M$2.31M
Long-term debt$927,000$2.81M
Total debt$4.48M$5.11M
Total liabilities$15.56M$9.93M
Shareholders' equity-$9.78M-$1.32M
Net debt$1.49M$3.41M
Shares outstanding3.07M655,262
Cash flow statement
Operating cash flow-$10.96M-$14.89M
Capital expenditure—$18,000
Free cash flow—-$14.91M
Investing cash flow$1.85M$4.71M
Financing cash flow$10.39M$6.44M
Depreciation & amortization$37,000$37,000
Stock-based compensation$60,000$686,000

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.